Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-02 phase IIb dose-ranging study in mesalazine-refractory ulcerative colitis
2008-007952-90Phase 2Completed
- Sponsor
- Lipid Therapeutics GmbH
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of phosphatidylcholine (LT-02) in autoimmune colitis (4 arms), sponsored by Lipid Therapeutics GmbH. Primary endpoint: Mean rounded SCCAI change from baseline to Week 12. Started Aug 2009; status: completed.
02
Drugs
phosphatidylcholine (LT-02)
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2008-007952-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007952-90.